Track 07 of 9
Gut Microbiome & Metabolism
Bacterial diversity, bile acids and metabolic health.
The gut microbiome is increasingly understood as a metabolic organ regulating energy harvest, bile acid signaling, and incretin secretion. The track will cover bile acid–FXR–FGF19 axis pharmacology, Akkermansia muciniphila supplementation trials, the durable microbiome shifts after RYGB and sleeve gastrectomy, and emerging fecal microbiota–derived therapeutics. Sessions will examine short-chain fatty acid signaling, the gut–brain axis and reward circuitry, and the interaction between microbiome composition and GLP-1 RA response. Methodologically, multi-omic integration and standardization of clinical microbiome trials will be addressed.
Focus areas
- Bile acid–FXR–FGF19 axis and obeticholic-class agents
- Akkermansia muciniphila and next-generation probiotics
- Microbiome shifts after RYGB and sleeve gastrectomy
- Short-chain fatty acids, gut–brain axis and reward signaling
- Microbiome predictors of GLP-1 RA response
- Fecal microbiota transplantation in metabolic disease
- Multi-omics and clinical trial standardization